AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Kelun-Biotech and Crescent Biopharma Partner to Develop Oncology Therapeutics
ByAinvest
Thursday, Dec 4, 2025 7:54 am ET1min read
Kelun-Biotech and Crescent Biopharma have formed a strategic partnership to develop and commercialize novel oncology therapeutics. The companies will advance CR-001, a PD-1 x VEGF bispecific antibody, and SKB105, an integrin beta-6-directed antibody-drug conjugate, in global markets and China. The collaboration aims to accelerate and expand the development of synergistic combinations with CR-001 and ADCs. CR-001 and SKB105 are on track to enter Phase 1/2 monotherapy clinical trials in Q1 2026, followed by combination studies.
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet